

# Advancements In Biodegradable Nanoparticles for Targeted Drug Delivery: A Comprehensive Review on Ulcerative Colitis Treatment.

Bhavya Bathula\*<sup>1</sup>, Dr. Varalaxmi. S<sup>2</sup>

<sup>1</sup>School of Pharmacy, Mohan Babu University, Sree Sainath Nagar, Tirupati, Andhra Pradesh 517102.

<sup>2</sup>School of Pharmacy, Mohan Babu University, Sree Sainath Nagar, Tirupati, Andhra Pradesh 517102

*Received: 20th Oct, 2025; Revised: 15th Dec, 2025; Accepted: 17th Jan, 2026; Available Online: 15th Feb, 2026*

## ABSTRACT

Ulcerative colitis (UC) is a chronic inflammatory bowel disease that poses a major challenge in the treatment as it is recurring and conventional treatments have limitations. The delivery of drugs in targeted form, especially the application of biodegradable nanoparticles therapy, can be hopeful in the future to increase the therapeutic effects and reduce the side effects. In this review, the authors have given a detailed account of the current developments in the field of biodegradable nanoparticles used in delivery of targeted drugs to treat ulcerative colitis. We discuss several categories of biodegradable nanoparticles, such as liposomes, polymeric nanoparticles, and nanogels with references to their benefits in biocompatibility, controlled drug release, and delivery to inflamed colonic tissues. Moreover, the review addresses the design, modification techniques of surfaces, and action mechanisms of nanoparticles which increase specificity to UC lesions. Clinical potential of these nanoparticles is also assessed by the article, identifying the problems, regulatory issues and future perspectives of clinical translations of these nanoparticles. Through the synthesis of existing literature, we give an insight into the possibility of biodegradable nanoparticles to transform the treatment of ulcerative colitis into the new stage of personalized and effective therapeutic interventions..

**Keywords:** Biodegradable Nanoparticles, Targeted Drug Delivery, Ulcerative Colitis, Controlled Release, Nanomedicine, Polymeric Nanoparticles, Liposomes, Nanogels, Inflammatory Bowel Disease, Drug Targeting Strategies, Colonic Drug Delivery, Therapeutic Nanocarriers..

**How to cite this article:** Bathula B, Varalaxmi S., Advancements In Biodegradable Nanoparticles for Targeted Drug Delivery: A Comprehensive Review on Ulcerative Colitis Treatment...Int J Drug Deliv Technol. 2026; 16(2): 294-302; DOI: 10.25258/ijddt.16.2.31

**Source of support:** Nil.

**Conflict of interest:** None

## INTRODUCTION

Ulcerative colitis (UC) is a chronic and inflammatory bowel disease (IBD) with constant inflammation and ulceration of the colonic mucosa and usually affects the colon and the rectum. UC is a condition that presents great difficulties in treatment because it has erratic course, side effects of treatment used, as well as ineffectiveness of treatment. The common treatment regimens, such as corticosteroids, immunosuppressive therapy, and Biologics, are not long-term therapies and accompanied with systemic side effects. This highlights the necessity of having better and more focused treatment methods.

Over the past couple of years, biodegradable nanoparticles (NPs) have developed as a promising vehicle in targeted drug delivery with enormous gains in stability of the drugs, active delivery, and target specificity. These nanoparticles have a number of important benefits when compared with other traditional ways of delivering drugs, including higher bioavailability, decreased systemic toxicity, and increased drug infiltration of particular areas of inflammation in the colon. Biodegradable nanoparticles are suitable treatment of UC as they reduce the likelihood of long-term


accumulation and toxicity associated with long-term accumulations, which are caused by the use of materials that naturally degrade in the body.

Nanoparticles of liposomes, polymeric nanoparticles, and nanogels can be designed to address the disadvantage of conventional therapy by delivering drugs to inflamed regions of the colon and provide specific and localized therapy. Nanoparticles can also be used to enhance the stability of drugs, cellular internalization, and sustained release on the site of action by altering their surfaces and using the right types of drug carriers. Moreover, personalized treatment regimens which nanoparticle design can afford bring hopeful future possibilities to better UC management.

This review entails a detailed discussion on biodegradable nanoparticles to be used in targeted drug delivery in the treatment of UC. It will address different forms of biodegradable nanoparticles, their action and the benefits of using such systems in delivering drugs to colon. The review will also cover the obstacles and future horizons in the

\*Author for Correspondence: bathulabhavya@gmail.com

development of nanoparticle-based therapies of UC based on their clinical potential



**Figure 2: Mechanisms of Action of Biodegradable Nanoparticles in UC Treatment**

## LITERATURE REVIEW

UC is a relapsing chronic inflammatory bowel disease (IBD) predominantly attacking the colon and the rectum. The precise etiology of the UC is still not clearly known but it is said to have a combination of genetic disposition, dysregulation of the immune system and environmental influences. Traditional treatments like corticosteroids, immunosuppressive medicines, and biologics offer symptomatic relief and in most situations are linked to serious side effects and ineffective long-term results. Such restrictions have highlighted the importance of new and more focused drug delivery systems to enhance treatment results and reduce side effects. Bio-degradable nanoparticles have created a ray of hope in the creation of targeted therapeutic drug delivery techniques of UC treatment.

Biodegradable nanoparticles refer to machines that are nanoscale that deliver therapeutic agents to the target site without exposing the whole body to toxicity or systemic exposure. These nanoparticles break down to harmless products and they do not cause any serious accumulation of these products in the body with time thus they would be the best solution in long term therapies. The main benefits of biodegradable nanoparticles consist in their capability to entrap a big variety of therapeutic agents, controlled release, and specificity to certain inflammatory sites in the colon. These properties render them particularly appropriate to such circumstances as UC, where local therapy is very essential in controlling the disease.

The biodegradable nanoparticles of various types have been formed and explored to be in use in UC therapy. The most

common type to be studied is the liposomes; these are the spherical vesicles that consist of phospholipid bilayers. Liposomes are especially useful in virtue of being biocompatible and of their capability of carrying around hydrophilic and hydrophobic drugs. They also could be surface-modified to have better capabilities of targeting inflamed colonic tissues. It has been demonstrated that liposomes have the ability of enhancing the stability and bioavailability of corticosteroids and immunosuppressive drugs and thus, would be an appealing method in the treatment of UC.

Another promising method of drug delivery is polymeric nanoparticles, based on biodegradable polymer, including poly(lactic-co-glycolic acid) (PLGA) and chitosan. The nanoparticles have a high level of drug release control, which results in sustained release and site-specific release in the colon. They can be altered on their surface to provide them with a higher stability, cell uptake, and targeting capability. The research has shown that polymeric nanoparticles are effective in delivering anti-inflammatory agents and biologics to inflamed colonic tissues and minimizing systemic exposure and associated side effects. The control of the release profile of these nanoparticles also enhances their application in the treatment of UC patients.

Nanoparticle Type	Drug Release Profile	Targeting Efficiency	Biodegradability	Size Range (nm)	Clinical Application
Liposomes	Controlled Release	High (surface modification)	High	50-500	Ongoing clinical trials
Polymeric Nanoparticles	Sustained Release	Moderate (receptor targeting)	High	100-1000	Preclinical studies
Nanogels	pH-Responsive Release	High (environmental triggers)	High	50-200	Early-stage research

**Table 1: Comparison of Types of Biodegradable Nanoparticles**

The other category of biodegradable nanoparticles is called nanogels and is composed of cross-linked polymer networks which are able to respond to environmental stimuli like changes in pH or certain enzymes. This renders them very appropriate to UC therapy since the inflamed areas of the colon tend to be of low PH than normal tissues. The nanogels are able to deliver their drug cargo when the environment becomes acidic which is a controlled and localized release of the drug which gives the nanogels a better therapeutic outcome. Moreover, nanogels have the advantage of being flexible enabling the encapsulation of a broad spectrum of drugs including biologics and small molecules enabling a flexible solution to UC treatment.

#### Future Perspectives

The biodegradable nanoparticle-based therapies have a bright future in the treatment of ulcerative colitis (UC), and a lot of opportunities exist to enhance the effect and individualization of treatment. Although biodegradable nanoparticles have proven to have a potential in preclinical and early clinical trials, there is a need to enhance continuous development of nanoparticles, targeting approaches and their use in practice to overcome the existing obstacles and achieve their full therapeutic potential.

Another important area of future study is the optimization of the nanoparticles design further to make them more efficient in terms of targeting and therapeutic effects. Modification in the technique of surface modification is the current research that aims at enhancing the specificity of nanoparticles in UC lesions. Increase in the accuracy of drug delivery will also depend on the use of specific ligands or antibodies to bind to overexpressed receptors on inflamed colonic tissues. Moreover, improvement of stimuli-responsive nanoparticles, releasing their drug cargo when exposed to certain stimuli, e.g. pH or enzyme presence, has high prospects of improving local drug delivery in UC. These systems have the potential to enable more stringent control of the release kinetics, as well as enhance the specificity of drug delivery.

Another interesting future research direction is the development of hybrid nanoparticle systems with the properties of various types of nanoparticles. A case in point is the integration of liposomes, polymeric nanoparticles and nanogels into a composite system as it has the potential of offering the advantages of both, e.g. better drug stability, increased bioavailability and stimuli-responsive release profiles without the drawbacks of each specific nanoparticle. Such composite systems may potentially

present more viable solutions to UC, and they include multi-mode drug delivery, which combats inflammation, minimizes the adverse effects, and improves the site of action drug release.

Innovations in personalized medicine will most probably have a major role in the future of nanoparticle-based therapy of UC. Personalized treatments based on the unique needs of particular patients will be possible to the extent that our knowledge of the disease and its heterogeneity will develop. Nanoparticles can be designed to attack biomarkers or disease-specific attributes in each patient, which can be treated more precisely and effectively. Moreover, customized nanoparticle preparations would help maximize the drug release characteristics according to the disease stage, inflammation, and treatment response of the patient with a better therapeutic effect at reduced side effects.

Another direction of biodegradable nanoparticles is the integration of sophisticated technologies, including artificial intelligence (AI) and machine learning, into its design and optimization. The analysis of large volumes of clinical trial, preclinical research, and patient outcomes data can be performed with the aid of AI to forecast the most successful nanoparticle formulations and treatment regimes. Machine learning algorithms may be used to determine the most effective surface modifications, drug encapsulation strategies and release kinetics, and to hasten the creation of personalized nanoparticle-based therapy of UC. Moreover, AI might also be helpful with optimization of nanoparticle formulations as it would model interactions with biological systems saving time and cost of experimental testing.

The other avenue that can be successfully developed in future is the combination of biodegradable nanoparticles with other forms of therapy, like in gene therapy or combination drug therapies. As an example, nanoparticles may be used to deliver not only classical anti-inflammatory but also biologics, gene-editing or small interfering RNA (siRNA) that specifically work with UC inflammatory pathways. Such a combination may provide a better holistic treatment as it would address all the various facets of the disease simultaneously to maximize the therapeutic potential and may result in eventual long-term remission in UC sufferers.

Although this has a bright future, there are still major challenges with regulatory approval and mass production of the biodegradable nanoparticles when they are to be applied clinically. It will also be necessary to have sustained cooperation between scientists, business executives and

regulatory authorities so as to make sure that therapies using nanoparticles are safe and effective. The need to simplify manufacturing technology, lower the cost of production and the need to come up with reliable methods of producing nanoparticles in a large scale will also play a great role in ensuring such therapies become more affordable to the larger group of patients. Also, clinical trials will be essential in establishing the safety and efficacy of nanoparticle-based therapies in the long-term, and future studies should be aimed at filling in the gaps in the information concerning the long-term results and adverse effects of the same.

Lastly, the realization of the potential and advantages of biodegradable nanoparticles within clinical practice will be dependent on the awareness of the public and clinicians towards the advantages and potential of these nanoparticles. Training and partnership between scientific community, health professionals and patients will be needed to help embrace and adopt nanoparticle-based therapies in the standard UC treatment. Moreover, the formulation of explicit rules on how these therapies should be employed in clinical set ups will contribute towards the effective and safe usage of these therapies in the care of patients.

In summary, there is immense potential in consideration of biodegradable nanoparticles in the future of UC treatment. Further development of nanoparticles in designing and incorporation with new technology will further increase their therapeutic applications. Nanoparticles are going to be produced with relative ease, their performance will be tailored to specific clinical requirements and clearance will be obtained to achieve the full clinical potential of such systems. With the ongoing research, biodegradable nanoparticles may be at the center of the future of revolutionizing the treatment of UC, which will provide more targeted, effective, and personalized therapies to the patients with this chronic and disability disease.

The therapeutic effects of biodegradable nanoparticles in the UC treatment are complex. When taken, nanoparticles will ensure that the drugs that are put up are not degraded until the targeted location. When these nanoparticles arrive at the inflamed areas of the colon, they will release their cargo in a regulated fashion such that the drugs have been directed to the places of action. This is achieved through surface-based transformations that enable the nanoparticles to target inappropriate surfaces on the tissues that are inflamed and increase drug delivery specificity. Also, there are numerous biodegradable nanoparticles, which have been optimized to react to the acidic conditions of the colon, which further improves the release of drugs in the target site.

Although biodegradable nanoparticles show procedural potential in UC treatment, various findings are still facing difficulties as far as their clinical translation is concerned.

Among the greatest challenges is the reproducibility of formulations of nanoparticles. To develop nanoparticles that may satisfy regulatory requirements, it is necessary to ensure that their quality and batches-to-batches homogeneity are consistent. Moreover, the scale of production of these nanoparticles has to be very high in order to render them commercially viable, which makes it difficult by itself. The regulatory authorization of the nanoparticle-based therapy is also a big challenge, since such preparations have to be rigorously tested to prove that they are safe and effective. Moreover, the issue of long-term safety of nanoparticles is also concerned, because their possible ability to induce immune system or to become toxic should be properly researched in clinical trials.

In the future, it is believed that the biodegradable nanoparticle-based UC treatment therapies have a bright future. The optimization of nanoparticles design, surface modification and targeting is an area of increasing research that aims to facilitate their therapeutic effectiveness. Moreover, recent progress in personalized medicine, in which the therapies based on nanoparticles are adjusted to the individual requirements of each patient, are predicted to make the overall impact on the treatment results. Another line of approach that can offer a more holistic method of treating UC and other inflammatory diseases is the creation of combination therapies, where nanoparticles are used to deliver a combination of therapeutic molecules into the body.

#### **Mechanisms of Action of Biodegradable Nanoparticles in UC Treatment**

The therapeutic efficacy of biodegradable nanoparticles in the treatment of ulcerative colitis (UC) is strongly related to how easily they are able to target the site of inflammation in the colon. The pathways that these nanoparticles act are multi-dimensional and they include passive and active targeting. These systems target the desired tissue by the use of the exclusive characteristics of the nanoparticles and the pathology of UC to provide the therapeutic agents with the least side effects.

Passive targeting is one of the most important processes upon which the biodegradable nanoparticles use to exercise their influence, which takes advantage of the effect of enhanced permeability and retention (EPR). This effect is due to the fact that inflamed tissues e.g. those in UC tend to have leaky blood vessels and lack lymphatic drainage. This property enables nanoparticles to concentrate better in the location of inflammation because the greater size of nanoparticles does not permit them to exit the leaky vasculature in an effortless manner. This accumulation is passive and causes increased concentrations of drugs at the target site, and low levels of exposure to normal tissues and decreased systemic toxicity.

Surface Modification Technique	Targeting Mechanism	Advantages	Challenges
PEGylation	Improved stability, reduced opsonization	Increased circulation time, biocompatibility	Potential immune system interaction
Antibody Conjugation	Specific receptor targeting	High specificity, enhanced targeting efficiency	Complex manufacturing and cost

<b>Ligand-Based Targeting</b>	Receptor-mediated targeting	High targeting accuracy	Potential variability	receptor
-------------------------------	-----------------------------	-------------------------	-----------------------	----------

**Table 3: Comparison of Nanoparticle Surface Modification Techniques for Targeting UC**

Besides passive targeting, biodegradable nanoparticles may also use active targeting. Receptors are overexpressed by inflamed colonic tissues, surface modification of nanoparticles allows its selection, e.g., conjugation of certain ligands, antibodies or peptides. Indicatively, certain receptors like integrins or cell adhesion molecules can be enhanced in the lesions of UC and that provides the means by which nanoparticles can target the inflamed tissue. With these targeting ligands, nanoparticles can be designed to enhance the specificity and affinity to the inflamed tissues, which will precisely and efficiently deliver the therapeutic agents to the target location.

The other significant mechanism of action is pH - responsive drug release. Inflamed colon has a low PH than healthy tissue and this can be used by some of the biodegradable nanoparticles to produce the release of the encapsulated drugs. Nanoparticles like nanogels or pH-sensitive liposomes are made to be stable at basic or neutral pH, but dissolve their drug cargo in the acidic inflamed colon environment. The release of this PH-sensitive can provide a guarantee of the drugs being released into the site of action at the right time, thus increasing the efficacy of the drug and increasing the duration of action in the target site. Biodegradation of biodegradable nanoparticles is also a vital part of its action. Such nanoparticles are commonly constructed of polymers or lipids, which break down to non-toxic byproducts once their purpose is achieved. This biodegradation is slow and this means that it has the ability to release drugs slowly and in a controlled manner over time. The biodegradable nanoparticle’s ability to deliver the drug at a continued period of time is useful in the treatment of UC, wherein inflammation may last over prolonged periods. The rate of release of the nanoparticles can be adjusted as the nanoparticles degrade to suit the intensity of the inflammation, thus offering a tailored treatment.

Moreover, the surface charge of nanoparticles, as well as their size, can play a major role in cellular absorption and transport in tissues. Smaller nanoparticles which usually range 50 200 nm can enter into the mucus layer of the colon easier and be absorbed by the epithelial cells that line the gut easier. As well, the surface charge may influence the interaction of nanoparticles with negatively charged cell membranes. Through the optimization of these physical properties, nanoparticles may be made to be more stable in the gastrointestinal tract as well as have increased bioavailability to ensure the therapeutic agents are able to reach the site of inflammation.

The combination of these processes facilitates more effective, targeted, and controlled delivery of drugs to the treatment of ulcerative colitis using biodegradable nanoparticles. These nanoparticles offer a massive

breakthrough in the treatment of UC by reducing systemic side effects, enhancing the stability of drugs, and guaranteeing their release where they are more needed, i.e. the site of inflammation. Nevertheless, the specific regulation of such processes including proper targeting and the reduction of premature drug release has yet to be tackled and the clinical success of nanoparticle-based therapies based on this regulation has to be improved.

**Clinical Potential and Challenges**

There has been considerable potential in preclinical and early clinical studies of biodegradable nanoparticles as a new method of targeted drug delivery in the treatment of ulcerative colitis (UC). Their capacity to enhance the bioavailability of substances and decrease systemic toxicity and provide localized therapy to inflamed tissues makes them a possible breakthrough in the UC management. Nevertheless, with all these potentialities, there are a number of challenges that still exist and which will have to be addressed before these nanoparticles can be successfully converted into regular clinical applications.

Among the main benefits of biodegradable nanoparticles in the treatment of UC, it is possible to note the ability to deliver drugs to the inflammatory region of the colon, reducing the systemic adverse effects. Drugs like corticosteroids and immunosuppressants used in conventional UC therapies tend to affect the body in a broad way and thus cause undesirable side effects like immunosuppression, loss of bone, and predisposition to infection. The systemic exposure is reduced by the use of nanoparticles to package these drugs and deliver them directly to the inflamed regions in the colon and results in reduced side effects and patient compliance. Moreover, the biodegradable nanoparticles have controlled release properties which means that the drug can be delivered in a continuous delivery over a prolonged time period enhancing the efficacy of the therapy and decreasing the frequency of dosage.

Notwithstanding these benefits, biodegradable nanoparticles have some challenges during clinical translation in treatment of UC. The reproducibility and consistency of nanoparticle formulations is one of the most important problems. Nanoparticles are commonly prepared in small batch in preclinical studies in controlled laboratory settings. But at the scale of producing nanoparticles on clinical use, it becomes more complicated to preserve the same quality, uniformity and performance of the nanoparticles. The size of the particles, the encapsulation efficiency, and the release mechanisms of nanoparticles can alter the therapeutic and safety aspects of the nanoparticles, and therefore it is important to come up with sound manufacturing protocols that can guarantee consistency.

<b>Advantages of Biodegradable Nanoparticles</b>	<b>Challenges in Clinical Use</b>
<b>Targeted delivery to inflamed tissues</b>	Formulation reproducibility
<b>Reduced systemic toxicity</b>	Large-scale production challenges
<b>Controlled and sustained drug release</b>	Regulatory hurdles and approval process

<b>Biodegradable and non-toxic byproducts</b>	Potential immune response to nanoparticles
<b>Personalized treatment options</b>	Long-term safety concerns

**Table 2: Advantages and Challenges of Biodegradable Nanoparticles in UC Treatment**

The other issue is the massive manufacturing of biodegradable nanoparticles. Commercial scale production of nanoparticles involves complex equipments and processes which can produce high quality and quantity of nanoparticles. Besides, the production cost may be a constraining factor because the existing methods of fabricating nanoparticle could be costly. Cost effective processes of manufacturing the nanoparticles must also be developed to make them commercially viable, this may be through optimization of materials, increasing the scale of production methods and the decreasing the total production costs.

There is also a major challenge of regulatory approvals of the nanoparticle-based therapies. Nanoparticles are viewed as an innovative drug delivery system and therefore they are subject to high levels of regulatory scrutiny. To prove the safety, efficacy, and long-term toxicity of nanoparticle-based therapies, regulatory authorities (including the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA) demand a great deal of preclinical and clinical data. Due to the peculiarities of nanoparticles, including the fact that they can concentrate in particular tissues and can cause immune reactions, extensive research of the toxicity, biodegradation, and pharmacokinetics of nanoparticles is required before they can be used in clinical practice. Also, the long-term safety of nanoparticles in patients with chronic conditions such as UC is a critical issue and more studies are necessary to determine their compounding effects over a period of time.

One more problem is the immune reaction to nanoparticles. Though biodegradable nanoparticles are supposed to break down to non-toxic byproducts, the components of these particles, including the polymeric materials or the surface-modifying agents, may also cause immune reactions in certain people. The immune system of the body can treat these nanoparticles as foreign substances which causes inflammation or formation of anti-nanoparticle antibodies. These immune responses might decrease the efficiency of the nanoparticles and have undesirable impacts. In an attempt to curb this, surface alterations may be resorted to enhance biocompatibility and low immunogenicity, which is still under research.

Additionally, despite the high potential of the idea of targeted drug delivery by biodegradable nanoparticles, targeting is a difficult task to accomplish. Active targeting performance relies on the type of the ligands or antibodies that are being employed in order to modify the surface of the nanoparticles. The heterogeneity of the UC lesions, with the inflammation taking different severity levels all over the colon, complicates the aspect of uniform targeting. Also, the factors that may affect the penetration of nanoparticles through the mucus layer of the gut and cellular uptake by the inflamed tissues include the size of the nanoparticles, the surface charge and the composition of the drug being delivered. The optimization of these factors to achieve the specificity of targeting and increase the therapeutic outcomes is a subject of ongoing research.

Finally, patient-specific issues, including the disease stage, the level of inflammation and the co-occurrences can contribute to the success of nanoparticle-based therapies. A way to optimize the use of biodegradable nanoparticles in the treatment of UC would be the individualized medicine approach where the treatment is customized to individual patients depending on the individual characteristics. Such personalized treatments would however necessitate the creation of diagnostic instruments to determine the unique needs of individual patients and the capacity of tailoring the nanoparticle formulations to suit such needs.

To sum up, biodegradable nanoparticles have enormous potential to revolutionize the treatment of UC, but various clinical issues need to be countered before they can be used in mass practice. The key to ensuring that these therapies can be translated into the clinical setting successfully will be addressing the problems of formulation consistency, large-scale production, regulatory approval, immune response, and targeting efficiency. Further study of nanoparticle design, production and individualized approach to the treatment will aid to discover the full possibilities of biodegradable nano particles in UC and other inflammatory disease treatment.

**Future Perspectives**

The outlook of the biodegradable nanoparticles-based therapies in the treatment of ulcerative colitis (UC) seems to have been positive and there are many opportunities to enhance the effectiveness and personalization of the treatment. Although biodegradable nanoparticles have performed remarkably in both preclinical and early clinical studies, further improvements in the design of nanoparticle, targeting and clinical delivery are needed to address the prevailing challenges and achieve their full therapeutic potential.

The optimization of nanoparticles design to make them more efficient in terms of targeting and therapeutic response is one of the most important future research directions. The research today is concentrated on how to enhance the surface modification methods to make nanoparticles more specific in uc lesions. Specific ligands or antibodies which bind specifically to receptors which are overexpressed on inflamed colonic tissues will be essential in enhancing accuracy of drug delivery. Moreover, the development of nanoparticles that respond to stimuli (reaction to the presence of a certain trigger, e.g., pH or enzymes) and the delivery of their drug cargo in this manner has immense potential to improve the local delivery of therapy to UC. They would enable a better control over the release kinetics and the specificity of drug delivery would be improved further.

Another promising future research is the development of hybrid nanoparticle systems that would unite the benefits of the various types of nanoparticles. The application of liposomes with polymeric nanoparticles and nanogels together as a single system can be taken as an example, which would have the advantages of each including increased drug stability, increased bioavailability, and

stimuli-responsiveness release but reduced the limitations of any single type of nanoparticle. The possibilities of these hybrid systems are that they would be able to offer more viable solutions to UC, whereby they would offer multi-modal delivery of drugs which would target inflammation, minimise the side effects, and also increase the amount of drug release at the location of action.

In the future, nanoparticle-based treatment of UC, personalized medicine is likely to make a major contribution. As our concept of the disease and its heterogeneity is constantly expanding, the individualized treatment methods based on a particular patient and his/her needs will become possible. It is possible to design nanoparticles to be targeted at certain biomarkers and disease-specific properties of an individual patient to deliver a more targeted and effective treatment. Also, patient-specific nanoparticle formulations would have the potential to streamline drug release profiles according to the disease stage, extent of inflammation and response to treatment of the patient, thereby translating into better therapeutic effect and lesser side effects.

Another horizon in this field is the integration of new technologies, including artificial intelligence (AI) and machine learning, in the design and optimization of biodegradable nanoparticles. Clinical trials, preclinical research, and patient outcomes data can be analysed by means of AI to determine the most effective nanoparticle formulations and treatment regimens. The machine learning algorithms would be useful to determine the most suitable surface modifications, encapsulation approaches and release profiles, thus aiding in the development of personalized nanoparticle-based therapies of UC. Moreover, AI might also be used to optimize nanoparticle preparations by modeling their interactions with biological systems, with experimental testing being less costly and less time-consuming.

The other promising field to be explored in the future is the combination of biodegradable nanoparticles with other therapeutic technologies, like gene therapy, or combination drug therapies. As an example, not only conventional anti-inflammatory medications but also biologics, gene-editing agents, or small interfering RNA (siRNA) that specifically interact with inflammatory pathways in UC could be delivered with the help of nanoparticles. This combination therapy may provide a more holistic form of treatment because it would help to address the various areas of disease simultaneously increasing the therapeutic efficacy which may result in lasting remission of UC patients.

Even with the bright perspectives, controlling approval and the industrial production of biodegradable nanoparticles are still major issues to the clinical use of the new technology. It will be necessary to continue the cooperation between researchers, industry leaders and regulatory bodies to make sure that nanoparticle-based therapies are safe and effective. The attempts to simplify the manufacturing procedure, minimize the cost of the production process, and devise methods to scale the fabrication of nanoparticles will play a vital role in making them more affordable to the general population of patients. Also, clinical trials will be in the spotlight in proving the safety and efficacy of nanoparticle-

based therapies in the long term and the gaps in data concerning the long-term consequences and adverse effects should be addressed in the ongoing research.

Lastly, the success of bio-nanoparticles integration into clinical practice will largely depend on the awareness of the benefits and potential of such bio-nanoparticles to the population and clinicians. Nanoparticle-based therapies will require educational programs and partnership among the scientific community, health care providers, and patients to help make them acceptable and adoptable in the standard treatment of UC. Besides this, formulation of guidelines that can guide the usage of these therapies within a clinical setting will enable in ensuring that these therapies are used effectively and safely in patient care.

Finally, biodegradable nanoparticles have enormous potential in making UC treatment successful in the future. The development of nanoparticles that are more advanced, individualized medicine, and the incorporation of the emerging technologies will further enhance their application in therapy. Addressing the challenges in the production of nanoparticles today, its efficiency, and regulatory acceptance of the systems will be key to achieving the complete clinical potential of such a system. With the ongoing development of research, it is expected that, in the future, biodegradable nanoparticles will take the centre stage in revolutionizing the therapy of UC, which will provide more focused, efficient, and customized treatment to patients with this chronic and debilitating illness.

## CONCLUSION

The biodegradable nanoparticles present a disruptive solution in the management of ulcerative colitis (UC), and it is an effective option in breaking the barrier of conventional drug delivery systems. The capacity to entrap therapeutic agents and transport them to the inflamed region of the colon greatly enhances drug stability, bioavailability, and therapeutic efficacy in addition to reducing the side effects that are emitted by the system. As mentioned, each of the different types of biodegradable nanoparticles, such as liposomes, polymeric nanoparticles, and nanogels, has its own benefits of controlled release, targeted delivery, and biocompatibility, which make them the best choices regarding UC treatment.

These nanoparticles have additional mechanisms of action, including passive and active targeting, pH-responsive release, and sustained drug delivery, that make them more effective in treating UC. Nevertheless, even with these benefits, biodegradable nanoparticles in clinical translation have a number of challenges, such as reproducibility of the formulation, scale, regulatory acceptability, immunogenicity, and targeting. The success of the obstacles mentioned above will demand further research, innovation, and cooperation between academia, industry, and regulatory authorities.

In the future, the combination of personalized medicine with biodegradable nanoparticles, adopted technologies, such as artificial intelligence (AI), and other therapeutic approaches are based on the premise of huge potential, such as genetic therapy or combinations. Such progress will lead

to the creation of better and more personalized treatment of UC that will eventually enhance patient outcomes and lessen the disease burden.

To sum up, biodegradable nanoparticles can be used to transform UC treatment into a more targeted, controlled, and personalized treatment. With the ongoing development of research, and as a remedy to the existing problems is discovered, nanoparticle-based therapies are set to have a great impact on the live upkeep of UC and other inflammatory illnesses. The future of these therapies is bright, and this gives renewed hope to patients who were previously frustrated with the shortcomings of traditional therapies.

## REFERENCE

1. Álvarez-Lorenzo, C., & Concheiro, A. (2012). Nanoparticles for drug delivery in the treatment of ulcerative colitis: A review. *International Journal of Nanomedicine*, 7, 2353–2372. <https://doi.org/10.2147/IJN.S37902>.
2. Dube, R., & Khan, W. (2015). Biodegradable polymeric nanoparticles: Advances in drug delivery systems. *Journal of Drug Delivery Science and Technology*, 30(1), 47-55. <https://doi.org/10.1016/j.jddst.2015.03.001>
3. Dhanapal, R., & Sriram, M. (2018). Liposomes and nanogels: Emerging drug delivery systems for the treatment of ulcerative colitis. *Pharmaceutical Research*, 35(2), 156-167. <https://doi.org/10.1007/s11095-017-2241-0>.
4. Boddu, S. H. S., & Singh, S. R. (2011). Targeted drug delivery: A promising approach for ulcerative colitis treatment. *International Journal of Pharmaceutical Sciences and Research*, 2(5), 89-98. <https://doi.org/10.1063/1.3552929>.
5. Wang, S. S., & Liu, L. (2019). Recent advancements in biodegradable nanoparticles for targeted drug delivery: Applications in inflammatory bowel disease. *Nanomedicine: Nanotechnology, Biology, and Medicine*, 15(6), 23-35. <https://doi.org/10.1016/j.nano.2019.03.002>.
6. Pillai, O., & Labhasetwar, V. (2004). Biodegradable nanoparticles for drug and gene delivery to cells and tissue: A review. *Advanced Drug Delivery Reviews*, 56(9), 1123-1137. <https://doi.org/10.1016/j.addr.2004.04.015>.
7. Pinto, S. A., & Carvalho, E. (2017). Polymeric nanoparticles in ulcerative colitis therapy: A step forward in drug delivery. *Journal of Controlled Release*, 264, 40–50. <https://doi.org/10.1016/j.jconrel.2017.07.025>.
8. Morin, D., & Gagne, D. (2018). Biodegradable liposomes in drug delivery systems: A comprehensive review. *Drug Development and Industrial Pharmacy*, 44(7), 1087-1095. <https://doi.org/10.1080/03639045.2018.1485190>.
9. Choudhury, H., & Saha, S. (2020). Polymeric nanoparticles: A review of biomedical applications in the treatment of inflammatory bowel disease. *European Journal of Pharmaceutics and Biopharmaceutics*, 148, 80-92. <https://doi.org/10.1016/j.ejpb.2020.01.010>.
10. Singh, S., & Singh, M. (2017). Recent advances in biodegradable nanoparticles for the treatment of inflammatory diseases: A review. *Pharmaceutical Nanocarriers*, 10(4), 54-66. <https://doi.org/10.1016/j.ijpharm.2017.03.054>.
11. Brennan, M. T., & Lee, W. J. (2016). Nanomedicine in ulcerative colitis: Advancements in drug delivery and targeting strategies. *Journal of Inflammatory Bowel Diseases*, 22(3), 540-553. <https://doi.org/10.1093/crohns/jiw019>.
12. Mandal, S., & Ray, P. (2019). Development of biodegradable nanogels for targeted delivery in ulcerative colitis: A potential therapy. *International Journal of Drug Delivery and Therapeutics*, 9(5), 1015-1024. <https://doi.org/10.5138/ijddt.2019.9.5.07>.
13. Gupta, M. K., & Mehta, A. (2015). Advances in nanocarrier-based drug delivery systems for inflammatory bowel diseases. *Journal of Nanomaterials*, 2015, 1-14. <https://doi.org/10.1155/2015/451637>.
14. Yao, J., & Zhang, J. (2014). Biodegradable nanoparticles in drug delivery and disease treatment: A review of recent advancements. *Biomedical Materials*, 9(6), 35-41. <https://doi.org/10.1088/1748-6041/9/6/062001>
15. Jiang, X., & Li, Y. (2016). Polymeric nanocarriers for targeting the gut: A new approach in the treatment of inflammatory bowel diseases. *Biomaterials*, 96, 12-22. <https://doi.org/10.1016/j.biomaterials.2016.04.030>.
16. El-Dakdouki, M., & Girgis, A. (2017). Biodegradable nanoparticles in inflammatory bowel disease therapy: Mechanisms and clinical considerations. *Journal of Pharmaceutical Sciences*, 106(4), 937-948. <https://doi.org/10.1016/j.xphs.2016.10.033>.
17. Fathi, M., & Salatin, S. (2018). Drug delivery systems in the treatment of inflammatory bowel diseases: Nanoparticles as promising carriers. *Colloids and Surfaces B: Biointerfaces*, 170, 180-192. <https://doi.org/10.1016/j.colsurfb.2018.06.029>.
18. Zhang, J., & Li, S. (2018). Advances in the development of biodegradable nanomaterials for ulcerative colitis treatment: Focus on controlled drug delivery. *Journal of Nanobiotechnology*, 16(1), 12. <https://doi.org/10.1186/s12951-018-0353-9>.
19. Zhang, W., & Tian, J. (2019). Nanomedicines for the treatment of inflammatory bowel disease: A comprehensive review of current strategies. *Biomaterials Science*, 7(3), 835-849. <https://doi.org/10.1039/C8BM01639F>
20. Iqbal, M., & Chen, Q. (2019). Role of biodegradable nanoparticles in the treatment of inflammatory bowel diseases. *Advanced Drug Delivery Reviews*, 148, 110-122. <https://doi.org/10.1016/j.addr.2019.03.010>.
21. Rijal, N., & Kim, H. (2020). Polymeric nanocarriers for ulcerative colitis therapy: A review of recent advancements. *Pharmaceutical Nanocarriers*, 11(2), 107-118. <https://doi.org/10.1016/j.ijpharm.2019.11.039>.
22. Tseng, H. F., & Wang, S. L. (2020). Recent advances in the use of nanomedicine in the treatment of inflammatory bowel diseases. *Therapeutic Delivery*, 11(5), 329-338.

29. <https://doi.org/10.4155/tde-2020-0024>.
30. Neelakantan, S., & Vyas, S. P. (2017). Advances in biodegradable polymeric nanoparticles for the treatment of IBD. *World Journal of Gastroenterology*, 23(13), 2315-2323. <https://doi.org/10.3748/wjg.v23.i13.2315>.
31. Chen, Y., & Zhang, L. (2017). A novel pH-responsive nanoparticle system for controlled drug release in ulcerative colitis treatment. *Biomacromolecules*, 18(4), 1111-1122. <https://doi.org/10.1021/acs.biomac.7b00111>.
32. Wang, Y., & Liu, X. (2020). Controlled release biodegradable nanoparticles for targeted therapy in inflammatory bowel diseases. *Pharmaceutics*, 12(1), 24. <https://doi.org/10.3390/pharmaceutics12010024>.
34. Bandyopadhyay, S., & Guha, A. (2018). Biodegradable nanoparticles for drug delivery in gastrointestinal diseases: An overview. *Journal of Nanoscience and Nanotechnology*, 18(6), 4175-4187. <https://doi.org/10.1166/jnn.2018.15793>.
35. Choudhury, H., & Shah, A. (2016). Polymeric nanoparticles in ulcerative colitis treatment: An evolving approach. *European Journal of Pharmaceutical Sciences*, 92, 53-68. <https://doi.org/10.1016/j.ejps.2016.06.022>.
36. Fernandez, S., & Aguado, A. (2019). Nanocarriers for targeted drug delivery in the treatment of ulcerative colitis: Current challenges and future perspectives. *Journal of Controlled Release*, 309, 91-105. <https://doi.org/10.1016/j.jconrel.2019.08.021>.
37. Li, X., & Chen, J. (2017). Exploring nanomedicine for targeted delivery in inflammatory bowel disease therapy. *Journal of Inflammatory Bowel Diseases*, 23(5), 903-915. <https://doi.org/10.1093/crohns/ijw104>.
38. Masi, L., & Salvatore, C. (2021). The future of nanomedicine in the treatment of inflammatory bowel diseases: Opportunities and challenges. *Pharmaceutical Research*, 38(6), 1678-1687. <https://doi.org/10.1007/s11095-021-03033-1>.